^
    Back
    Association details:
    Biomarker:MYC expression
    Cancer:Diffuse Large B Cell Lymphoma
    Drug:RG6146 (BET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    A Two Part Study of RO6870810. Dose-Escalation Study in Participants With Advanced Solid Tumors and Expansion Study in Participants With Selected Malignancies

    Excerpt:
    ...Histologically confirmed advanced aggressive B-cell lymphoma with abnormal MYC expression with persistent disease requiring treatment...
    Trial ID:
    NCT01987362
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Br J Cancer
    Title:

    A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma

    Published date:
    12/14/2020
    Excerpt:
    We conducted a Phase 1 study of RO6870810 administered subcutaneously administered subcutaneously for 21 or 14 days of 28- or 21-day cycles, respectively, in patients with…diffuse large B-cell lymphoma (DLBCL) with MYC deregulation….Objective response rates were...11% (2/19) for patients with...DLBCL....Responding tumours had evidence of deregulated MYC expression.
    DOI:
    10.1038/s41416-020-01180-1
    Trial ID:
    NCT01987362